Physitrack Group
Investor Relations

Shaping the future of digital health by building value for key stakeholders through innovation and sustainable business management.

Loading last update time…
The Share

Recent reports and webcasts

See all reports

Interim Report Q2

1st of January - 30th June 2025

Operational discipline and innovation drive €0.9m rebound, marking historical quarterly positive cash flow
Download Interim Report Q2
From 2024 Annual Report

Key financial highlights

Financial Targets
14
%

Year-on-year organic growth

€
1600
K

Total available liquidity

30
%

Operating cash flow (MSEK)

Physitrack Spotlight

Gain exclusive access to comprehensive insights that transcend conventional press releases through our Spotlight newsroom.

View all
September 10, 2025

Redeye Q1 2025 CEO Interview

Details

Redeye's Jessica Grunewald interviews CEO Henrik Molin on Q1 2025 report.

Past Spotlights

Redeye Q4 2024 CEO Interview

Redeye's analyst Jessica Grunewald interviews CEO Henrik Molin about Q4 2024 results.

Redeye High Quality Microcap Day CEO presentation

Henrik Molin, CEO, presents Physitrack and key processes at Redeye High Quality Microcap Day on March 26, 2025.

Redeye Q1 2025 CEO Interview

Redeye's Jessica Grunewald interviews CEO Henrik Molin on Q1 2025 report.